Arguedas A G, Zaleska M, Stutman H R, Blumer J L, Hains C S
Department of Pediatrics, Memorial Miller Children's Hospital, University of California, Irvine.
Pediatr Infect Dis J. 1991 May;10(5):375-80. doi: 10.1097/00006454-199105000-00006.
A total of 137 children with acute otitis media with effusion were randomly allocated to treatment with cefprozil (30 mg/kg/day divided into two equal doses), an investigational cephalosporin or amoxicillin clavulanate potassium (40 mg/kg/day divided into three equal doses) for 10 days. The most common pathogens obtained from middle ear cavities by tympanocentesis were Streptococcus pneumoniae (33%), Haemophilus influenzae (19.6%) and Moraxella catarrhalis (8.3%). Patients were scheduled for follow-up visits at midtreatment, at end of therapy and at 30 days. Of the 137 children 122 were evaluable. Five of 60 patients (8.3%) treated with cefprozil and 14 of 62 patients (22.5%) treated with amoxicillin clavulanate potassium were considered therapeutic failures because of persistence of symptoms and/or isolation of the original pathogen or superinfection (P = 0.05). Rates of relapse, reinfection and persistent middle ear effusion as documented by tympanogram were comparable in both groups. When persistent middle ear effusion was analyzed by pneumatic otoscopy, 64 of 103 affected ears (62.1%) treated with cefprozil and 80 of 105 affected ears (76.1%) treated with amoxicillin clavulanate potassium were abnormal (P = 0.04). Loose stools were more common in children treated with amoxicillin clavulanate potassium than in children treated with cefprozil (P = 0.0004). Based on the efficacy results from this study, the lower gastrointestinal side effects and the convenience of twice-a-day dosing, we believe that cefprozil in a dosage of 30 mg/kg/day divided every 12 hours represents a potential alternative for the treatment of acute otitis media with effusion in children.
137例急性分泌性中耳炎患儿被随机分为三组,分别接受头孢丙烯(30mg/kg/天,分两次等量给药)、一种研究用头孢菌素或阿莫西林克拉维酸钾(40mg/kg/天,分三次等量给药)治疗10天。通过鼓膜穿刺术从中耳腔获取的最常见病原体为肺炎链球菌(33%)、流感嗜血杆菌(19.6%)和卡他莫拉菌(8.3%)。患者计划在治疗中期、治疗结束时和30天时进行随访。137例患儿中,122例可进行评估。接受头孢丙烯治疗的60例患者中有5例(8.3%)、接受阿莫西林克拉维酸钾治疗的62例患者中有14例(22.5%)因症状持续和/或原病原体分离或发生二重感染而被视为治疗失败(P=0.05)。两组鼓膜图记录的复发率、再感染率和持续性中耳积液发生率相当。通过鼓气耳镜分析持续性中耳积液时,接受头孢丙烯治疗的103只患耳中有64只(62.1%)异常,接受阿莫西林克拉维酸钾治疗的105只患耳中有80只(76.1%)异常(P=0.04)。接受阿莫西林克拉维酸钾治疗的儿童比接受头孢丙烯治疗的儿童更容易出现腹泻(P=0.0004)。基于本研究的疗效结果、较低的胃肠道副作用以及每日两次给药的便利性,我们认为,剂量为30mg/kg/天、每12小时给药一次的头孢丙烯是治疗儿童急性分泌性中耳炎的一种潜在替代药物。